UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
November 5, 2019
(Commission File No. 001-38475)
ASLAN PHARMACEUTICALS LIMITED
(REG. NO. 289175)
(Translation of registrant’s name into English)
CAYMAN ISLANDS
(Jurisdiction of incorporation or organisation)
83 CLEMENCEAU AVENUE
#12-03 UE SQUARE
SINGAPORE 239920
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ☐ No ☒
Announcement of receiving the approval from FSC on issuance of ordinary shares for sponsoring the issuance of American Depository Receipts
|
1. |
Date of occurrence of the event: 2019/11/05 |
|
2. |
Company name: ASLAN PHARMACEUTICALS LIMITED |
|
3. |
Relationship to the Company: Head office |
|
4. |
Reciprocal shareholding ratios: NA |
|
5. |
Occurrence: Received official letter No.1080334435 from Financial Supervisory Committee R.O.C Taiwan (‘FSC’) for the approval on issuance of ordinary shares for sponsoring the issuance of American Depository Receipts. |
|
6. |
Next steps: Proceed per the official letter No.1080334435 from FSC on the issuance of ordinary shares for sponsoring the issuance of American Depository Receipts. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
ASLAN PHARMACEUTICALS LIMITED |
|
(Registrant) |
|
|
|
By: |
/s/ Kiran Kumar Asarpota
|
Name: |
Kiran Kumar Asarpota |
Title: |
VP Finance |
Date: November 5, 2019